Sign In
Buy ATHA
$6.61
+0 (+0%)
At Close: Apr 14, 2026
Athira Pharma Announces Proposed Settlement of Stockholder Derivative Action
05:00pm, Friday, 17'th May 2024
BOTHELL, Wash., May 17, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health a
Athira Pharma Reports First Quarter 2024 Financial Results and Pipeline and Business Updates
04:05pm, Wednesday, 15'th May 2024
Topline data from Phase 2/3 LIFT-AD clinical trial of fosgonimeton as a potential treatment for mild-to-moderate Alzheimer's disease expected in second half of 2024 Submitted Investigational New Dru
Athira Pharma to Participate in Upcoming May Conferences
07:00am, Thursday, 02'nd May 2024
BOTHELL, Wash., May 02, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health
Athira Pharma Appoints Javier San Martin, M.D., as Chief Medical Officer
07:00am, Monday, 15'th Apr 2024
BOTHELL, Wash., April 15, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health
Athira Pharma Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer's Disease
07:00am, Thursday, 11'th Apr 2024
BOTHELL, Wash., April 11, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health
Athira Pharma Announces Upcoming Poster Presentation at American Academy of Neurology (AAN) 2024 Annual Meeting
07:00am, Wednesday, 03'rd Apr 2024
Presentation to highlight therapeutic potential of Athira's small molecules targeting the neurotrophic HGF system in neurodegenerative disorders, including Alzheimer's disease, Parkinson's disease and
Athira Pharma Presents Clinical and Preclinical Data Supporting Therapeutic Potential of Fosgonimeton in Alzheimer's & Parkinson's Diseases at AD/PD™ 2024
Athira Pharma, Inc. (ATHA) is a Great Momentum Stock: Should You Buy?
01:01pm, Wednesday, 28'th Feb 2024
Does Athira Pharma, Inc. (ATHA) have what it takes to be a top stock pick for momentum investors? Let's find out.
Athira Pharma Reports Full Year 2023 Financial Results and Pipeline and Business Updates
04:05pm, Thursday, 22'nd Feb 2024
Enrollment completed in Phase 2/3 LIFT-AD clinical trial of fosgonimeton as a potential treatment for mild-to-moderate Alzheimer's disease; topline data expected in second half of 2024 On track to i
Athira Pharma Announces Publication in Frontiers in Neuroscience Highlighting Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS)
ATHA Energy unveils promising results from North Valour-East Project electromagnetic surveys amidst strategic uranium expansion
08:18am, Wednesday, 17'th Jan 2024
ATHA Energy Corp (CSE:SASK, OTCQB:SASKF) has announced results from its large-scale electromagnetic (EM) surveys at the 100%-owned North Valour-East Project in Saskatchewan's Athabasca Basin. The pro
Athira Pharma Provides 2024 Clinical Pipeline Outlook and Business Update
07:00am, Monday, 08'th Jan 2024
Completed enrollment in Phase 2/3 LIFT-AD clinical trial of fosgonimeton as a potential treatment for mild-to-moderate Alzheimer's disease and expects topline data in second half of 2024 Plans to in
Athira Pharma Completes Enrollment of Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer's Disease
07:00am, Wednesday, 03'rd Jan 2024
Topline data from LIFT-AD on track for second half of 2024 Previously reported independent, unblinded interim analysis supports trial continuation and potential clinically meaningful activity of fosgo
Exploratory findings add to increasing body of clinical and preclinical data supporting positive modulation of the neurotrophic HGF system as a potential therapeutic approach for neurodegenerative dis
These biotechs targeting multiple neurodegenerative diseases
08:15am, Friday, 01'st Dec 2023
Anyone who has struggled with a neurodegenerative disease (NDD) or has cared for someone who has one of these illnesses knows how challenging they are to treat and even diagnose. NDDs damage cognitive
